ViaCyte, Inc.
ViaCyte, Inc., a pioneering biotechnology company headquartered in the United States, focuses on innovative cell therapy solutions for diabetes management. Founded in 2004, ViaCyte has made significant strides in the development of its unique product offerings, including its lead product, PEC-Direct, which aims to restore insulin production in patients with type 1 diabetes. With a strong presence in the regenerative medicine sector, ViaCyte is dedicated to advancing its proprietary technologies that utilise stem cell-derived pancreatic islet cells. The company has garnered attention for its commitment to addressing the challenges of diabetes, positioning itself as a leader in the field. Through its groundbreaking research and development efforts, ViaCyte continues to make notable contributions to the future of diabetes treatment.
DitchCarbon Score
How does ViaCyte, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
ViaCyte, Inc.'s score of 51 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
ViaCyte, Inc., headquartered in the US, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. The company is a current subsidiary of Vertex Pharmaceuticals Incorporated, which may influence its climate commitments and reporting practices. While there are no documented reduction targets or specific climate pledges from ViaCyte, it is important to note that emissions data and sustainability initiatives may be cascaded from its parent company, Vertex Pharmaceuticals. This relationship suggests that ViaCyte may align its climate strategies with those of Vertex, which is actively engaged in sustainability efforts. As of now, ViaCyte's climate commitments remain unspecified, and the company has not publicly outlined any significant reduction initiatives or targets. The lack of emissions data and defined climate strategies highlights an opportunity for ViaCyte to enhance its environmental accountability and contribute to broader industry efforts in reducing carbon footprints.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | - | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | - | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | - | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
ViaCyte, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
